phase 111 top line results, page-2

These are really a first cut of the Phase-III results.

The announcement tells is: "a more detailed analysis of the Phase-III results by the end of the first quarter 2010.."

What we aren't seeing here is the % of patients with a viral load > 400 copies per ml. (as we will see when more details are out).

What we are seeing is that the CD4 count for Phase-III matches that of Phase-II.

So if we wanted the big bang, we're getting more sedate little bangs.

Do I understand correctly that this trial is now closed and there won't be any Phase-III 48 week data? Or is that yet to be determined once the regulators look over the 24 week data?

Big issue now is: what developments for commercialisation?